{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:02:45Z","timestamp":1783612965362,"version":"3.55.0"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,12,15]]},"DOI":"10.2169\/internalmedicine.9487-22","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T22:11:37Z","timestamp":1651875097000},"page":"3743-3747","source":"Crossref","is-referenced-by-count":1,"title":["Elevated White Blood Cell Count and Lactate Dehydrogenase Levels Are Important Markers for Diagnosing Relapse of Adult-onset Still's Disease under Tocilizumab Use"],"prefix":"10.2169","volume":"61","author":[{"given":"Sho","family":"Matsushita","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenei","family":"Sada","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Manabe","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Kashihara","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tagawa","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Akebo","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Minoda Sada","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Hatta","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol 4: 603-618, 2018.","DOI":"10.1038\/s41584-018-0081-x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77: 1720-1729, 2018.","DOI":"10.1136\/annrheumdis-2018-213920"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yamada H, Kaneko Y, Tamai H, Takeuchi T. Biomarkers for disease flare in patients with adult-onset Still's disease undergoing treatment with tocilizumab. Rheumatology (Oxford) 59: 440-442, 2020.","DOI":"10.1093\/rheumatology\/kez392"},{"key":"4","unstructured":"4. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 19: 424-430, 1992."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Li T, Gu L, Wang X, et al. A pilot study on tocilizumab for treating refractory adult-onset Still's disease. Sci Rep 7: 13477, 2017.","DOI":"10.1038\/s41598-017-13639-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Isaacs JD, Harari O, Kobold U, Lee JS, Bernasconi C. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther 15: R204, 2013.","DOI":"10.1186\/ar4397"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 16: 335-345, 2020.","DOI":"10.1038\/s41584-020-0419-z"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kim JW, Ahn MH, Jung JY, Suh CH, Kim HA. An update on the pathogenic role of neutrophils in systemic juvenile idiopathic arthritis and adult-onset Still's disease. Int J Mol Sci 22: 13038, 2021.","DOI":"10.3390\/ijms222313038"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Liu Y, Xia C, Chen J, Fan C, He J. Elevated circulating pro-inflammatory low-density granulocytes in adult-onset Still's disease. Rheumatology (Oxford) 60: 297-303, 2021.","DOI":"10.1093\/rheumatology\/keaa324"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Li S, Zheng S, Tang S, et al. Autoinflammatory pathogenesis and targeted therapy for adult-onset Still's disease. Clin Rev Allergy Immunol 58: 71-81, 2020.","DOI":"10.1007\/s12016-019-08747-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kasama T, Miwa Y, Isozaki T, Odai T, Adachi M, Kunkel SL. Neutrophil-derived cytokines: potential therapeutic targets in inflammation. Curr Drug Targets Inflamm Allergy 4: 273-279, 2005.","DOI":"10.2174\/1568010054022114"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Drent M, Cobben NA, Henderson RF, Wouters EF, Van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J 9: 1736-1742, 1996.","DOI":"10.1183\/09031936.96.09081736"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Maruyama A, Kokuzawa A, Yamauchi Y, et al. Clinical features of elderly-onset adult-onset Still's disease. Mod Rheumatol 31: 862-868, 2021.","DOI":"10.1080\/14397595.2020.1829340"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sugiyama T, Furuta S, Hiraguri M, et al. Latent class analysis of 216 patients with adult-onset Still's disease. Arthritis Res Ther 24: 7, 2022.","DOI":"10.1186\/s13075-021-02708-3"},{"key":"15","unstructured":"15. Farhana A, Lappin SL. Biochemistry, lactate dehydrogenase. 2021 May 7. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, 2022 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32491468\/"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Motoo Y, Ohta H, Okai T, Sawabu N. Adult-onset Still's disease: hepatic involvement and various serum markers relating to the disease activity. Jpn J Med 30: 247-250, 1991.","DOI":"10.2169\/internalmedicine1962.30.247"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nagamine R, Chen W, Hara T, Kondo K, Sugioka Y. Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases. Mod Rheumatol 19: 348-350, 2009.","DOI":"10.1007\/s10165-009-0159-z"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Mitrovic S, Fautrel B. New markers for adult-onset Still's disease. Joint Bone Spine 85: 285-293, 2018.","DOI":"10.1016\/j.jbspin.2017.05.011"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Girard C, Rech J, Brown M, et al. Elevated serum levels of free interleukin-18 in adult-onset Still's disease. Rheumatology (Oxford) 55: 2237-2247, 2016.","DOI":"10.1093\/rheumatology\/kew300"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tang KT, Hsieh CW, Chen HH, et al. The effectiveness of tocilizumab in treating refractory adult-onset Still's disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response. Clin Rheumatol 41: 557-566, 2022.","DOI":"10.1007\/s10067-021-05921-2"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/24\/61_9487-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T03:23:42Z","timestamp":1671247422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/24\/61_9487-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":20,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9487-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"article-number":"9487-22"}}